External control arms in oncology: current use and future directions
Pallavi S. Mishra‐Kalyani(Center for Drug Evaluation and Research), Julia A. Beaver(Center for Drug Evaluation and Research), Amna Ibrahim(Beni-Suef University), John Concato(United States Food and Drug Administration), R. Angelo DeClaro(United States Food and Drug Administration), Harpreet Singh(United States Food and Drug Administration), Shenghui Tang(United States Food and Drug Administration), Richard Pazdur(United States Food and Drug Administration), L. Amiri Kordestani(United States Food and Drug Administration), Paul G. Kluetz(United States Food and Drug Administration), Donna R. Rivera(National Cancer Institute), R. Sridhara(United States Food and Drug Administration), Yuan Li Shen
Cited by 132
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k